MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Phase 1
Completed
Conditions
Hepatitis C
First Posted Date
2007-08-21
Last Posted Date
2015-08-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
40
Registration Number
NCT00518622

MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)

Phase 1
Completed
Conditions
Advanced Cancer
First Posted Date
2007-08-21
Last Posted Date
2015-03-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
25
Registration Number
NCT00518739

Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)

Phase 2
Terminated
Conditions
Mediastinitis
Bacteremia
Staphylococcus Aureus
Interventions
Biological: Placebo
Biological: V710
First Posted Date
2007-08-21
Last Posted Date
2015-10-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
8031
Registration Number
NCT00518687

Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)

Phase 3
Completed
Conditions
Cervical Cancer
Genital Warts
First Posted Date
2007-08-16
Last Posted Date
2017-03-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1877
Registration Number
NCT00517309

An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: MK-0941
Drug: Placebo
Drug: LANTUS insulin
First Posted Date
2007-08-06
Last Posted Date
2015-07-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
70
Registration Number
NCT00511472

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: MK0941
First Posted Date
2007-08-06
Last Posted Date
2016-08-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
70
Registration Number
NCT00511667

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus (T2DM)
First Posted Date
2007-08-03
Last Posted Date
2017-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
211
Registration Number
NCT00511108

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
End-Stage Kidney Disease
Interventions
Drug: Sitagliptin
Drug: Glipizide
First Posted Date
2007-07-31
Last Posted Date
2017-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
129
Registration Number
NCT00509236

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Phase 3
Completed
Conditions
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
Interventions
Drug: Sitagliptin
Drug: Glipizide
Drug: Placebo for Sitagliptin
Drug: Placebo for Glipizide
First Posted Date
2007-07-31
Last Posted Date
2017-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
426
Registration Number
NCT00509262

A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)

Phase 3
Completed
Conditions
Insomnia
Interventions
Drug: Esmirtazapine
Drug: Placebo
First Posted Date
2007-07-25
Last Posted Date
2018-10-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
419
Registration Number
NCT00506389
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy